First, we determined whether the frequencies of these B cell subsets within the memB cell pool were altered in MS patients following treatment with anti-CD20 (Rituximab, MS-R) or anti-CD49d (Natalizumab, MS-N) (Figure 1B) compared to HCs. Here, RND3 is linked to myeloid sarcoma.